Design World

  • Home
  • Technologies
    • 3D CAD
    • Electronics • electrical
    • Fastening & Joining
    • Factory automation
    • Linear Motion
    • Motion Control
    • Test & Measurement
    • Sensors
    • Fluid power
  • Learn
    • Ebooks / Tech Tips
    • Engineering Week
    • Future of Design Engineering
    • MC² Motion Control Classrooms
    • Podcasts
    • Videos
    • Webinars
  • LEAP AWARDS
  • Leadership
    • 2022 Voting
    • 2021 Winners
  • Design Guide Library
  • Resources
    • 3D Cad Models
      • PARTsolutions
      • TraceParts
    • Digital Issues
      • Design World
      • EE World
    • Women in Engineering
  • Supplier Listings

How A Drug Company Schemed To Sell A Potent Opioid To Fake Cancer Patients

By Meagan Parrish | September 18, 2017

Share

A report released earlier this month has detailed the various ways a pharmaceutical company allegedly schemed to illegally sell a highly addictive fentanyl spray.

According to the report, which was issued by Sen. Claire McCaskill, D-Mo., Insys Therapeutics repeatedly bribed doctors, falsified patient files, and misled insurers in order to boost prescriptions for its fentanyl spray called Subsys.

The report, based on several civil and criminal lawsuits, reveals Insys, starting in 2014, created an internal workforce that would aggressively seek authorization from insurers to cover use of the drug.

Prior-authorization of Subsys is required because the drug is expensive and insurance companies often want to make sure that other alternatives have been tried. Subsys has been approved for use in cancer patients over 18 experiencing extreme “breakthrough” pain. The patient has to already be on other opioid medications that are not adequately treating the pain. 

In this April 12, 2017, file photo, U.S. Sen. Claire McCaskill, D-Mo., speaks to the media following a town hall meeting in Hillsboro, Mo. McCaskill released the report that called out the kickback scheme. (Image credit: AP Photo/Jeff Roberson, File)

In order to assure more patients had access to Subsys, Insys’ unit would partner with doctors and lead insurance representatives to believe that a certain patient had cancer and was in urgent need of the drug — but often the patients didn’t actually have cancer. The report claims that Insys tricked insurance companies into believing they did, however, by using key phrases like “breakthrough pain.” Insys representatives also made sure to call insurance companies from a phone that wouldn’t show their number, so that insurers wouldn’t see that they were being contacted by the drug’s manufacturer.

One patient involved in a lawsuit against a doctor who took part in the scheme said that he was pressured to take Subsys even though there were less risky options. The patient did not have cancer and had been seeking treatment for gastrointestinal pain. The suit alleges that the doctor in question received more than $200,000 in speaking fees and other expenses from Insys.

According to a report in Quartz, McCaskill wanted to release the report, called, “Fueling an Epidemic: Insys Therapeutics and the Systemic Manipulator of Prior Authorization,” in order to highlight how pharmaceutical companies have contributed to the opioid epidemic. 


Filed Under: Industry regulations

 

Related Articles Read More >

ids-industrial-camera-manufacturer.sustainability-3
IDS focuses on sustainability in shipping
Part 5: Motion control + MQTT, OPC-UA, and other protocols for cloud services
Facebook CEO Zuckerberg Calls for More Outside Regulation
Musk’s Boring Company Calls it Quits on LA Tunnel, Instead Focuses on Hyperloop

DESIGN GUIDE LIBRARY

“motion

Enews Sign Up

Motion Control Classroom

Design World Digital Edition

cover

Browse the most current issue of Design World and back issues in an easy to use high quality format. Clip, share and download with the leading design engineering magazine today.

EDABoard the Forum for Electronics

Top global problem solving EE forum covering Microcontrollers, DSP, Networking, Analog and Digital Design, RF, Power Electronics, PCB Routing and much more

EDABoard: Forum for electronics

Sponsored Content

  • Global supply needs drive increased manufacturing footprint development
  • How to Increase Rotational Capacity for a Retaining Ring
  • Cordis high resolution electronic proportional pressure controls
  • WAGO’s custom designed interface wiring system making industrial applications easier
  • 10 Reasons to Specify Valve Manifolds
  • Case study: How a 3D-printed tool saved thousands of hours and dollars

Design World Podcasts

May 17, 2022
Another view on additive and the aerospace industry
See More >
Engineering Exchange

The Engineering Exchange is a global educational networking community for engineers.

Connect, share, and learn today »

Design World
  • Advertising
  • About us
  • Contact
  • Manage your Design World Subscription
  • Subscribe
  • Design World Digital Network
  • Engineering White Papers
  • LEAP AWARDS

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Design World

  • Home
  • Technologies
    • 3D CAD
    • Electronics • electrical
    • Fastening & Joining
    • Factory automation
    • Linear Motion
    • Motion Control
    • Test & Measurement
    • Sensors
    • Fluid power
  • Learn
    • Ebooks / Tech Tips
    • Engineering Week
    • Future of Design Engineering
    • MC² Motion Control Classrooms
    • Podcasts
    • Videos
    • Webinars
  • LEAP AWARDS
  • Leadership
    • 2022 Voting
    • 2021 Winners
  • Design Guide Library
  • Resources
    • 3D Cad Models
      • PARTsolutions
      • TraceParts
    • Digital Issues
      • Design World
      • EE World
    • Women in Engineering
  • Supplier Listings